AA
FOMX

ALPS Advisors’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

ALPS Advisors’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,976
Closed -$155K – 797
2017
Q1 		$155K Sell
31,976
-3,197
-9% -$30.8K ﹤0.01% 714
2016
Q4 		$390K Buy
+35,173
New +$331K ﹤0.01% 610
2016
Q2 		– Sell
-34,363
Closed -$224K – 646
2016
Q1 		$224K Sell
34,363
-5,890
-15% -$38K ﹤0.01% 597
2015
Q4 		$326K Sell
40,253
-6,836
-15% -$51.1K ﹤0.01% 643
2015
Q3 		$3.45K Buy
47,089
+17,243
+58% +$176K ﹤0.01% 639
2015
Q2 		$306K Buy
+29,846
New +$330K ﹤0.01% 654

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ALPS Advisors's FOMX Position: Q2 2017 in Review

ALPS Advisors sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2017, closing a stake of 31,976 shares — an estimated $155K sold.

ALPS Advisors first reported a position in FOMX in Q2 2015 and held it in 6 quarters. The position peaked at $390K in Q4 2016. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2017.

  • ALPS Advisors reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • ALPS Advisors sold 31,976 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2017, an estimated $155K.
  • ALPS Advisors first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 6 quarters.
  • ALPS Advisors's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $390K in Q4 2016.
  • 56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2017.

Based on ALPS Advisors's 13F filing for Q2 2017, filed 3 Aug 2017.